Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Int J Chron Obstruct Pulmon Dis · 2012 · PMC3276258 · PMID 22334770

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

marginally significantP = 0.052so close (0.05 < p ≤ 0.1)

Treatment advantages were marginally significant for MF/F 400/10 versus F 10 ( P = 0.052) and MF/F 200/10 versus F 10 ( P = 0.063) adjusting for smoking and study.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.